Protalix BioTherapeutics
PLX
$1.15
Share price
-2.54%
Change (1 day)
-58.63%
Change (1 year)
Categories
Protalix BioTherapeutics (PLX) - Total debt
Total debt on the balance sheet as of December 2023 : $26.28 M
According to Protalix BioTherapeutics 's latest financial reports the company's total debt is $26.28 M. A company’s total debt is the sum of all current and non-current debts.
Protalix BioTherapeutics - Total debt on balance sheet (from 2011 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $26.28 M | -21.49% |
| 2022-12-31 | $33.47 M | 0.01% |
| 2021-12-31 | $33.47 M | -48.03% |
| 2020-12-31 | $64.4 M | 5.7% |
| 2019-12-31 | $60.92 M | 27.02% |
| 2018-12-31 | $47.96 M | -8.09% |
| 2017-12-31 | $52.18 M | -28.72% |
| 2016-12-31 | $73.21 M | 1.55% |
| 2015-12-31 | $72.09 M | 7.05% |
| 2014-12-31 | $67.35 M | 0.45% |
| 2013-12-31 | $67.04 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $70.84 B | 269,467.37% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $0.42 B | 1,530.07% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | $0.44 B | 1,593.46% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | $20.15 B | 76,582.77% | 🇮🇱 Israel |